Do Analysts Think You Should Buy - Infinity Pharmaceuticals, Inc., (NASDAQ: INFI)

Lloyd Doyle
March 9, 2018

Analysts await Infinity Pharmaceuticals, Inc.

What to Expect From Infinity Pharmaceuticals, Inc. The stock has "Equal-Weight" rating by Morgan Stanley on Wednesday, June 15. Wells Fargo upgraded Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.is a part of Healthcare sector and belongs to Biotechnology industry. The rating was maintained by Wedbush on Thursday, February 25 with "Neutral". The firm has "Market Perform" rating by William Blair given on Wednesday, June 15. After $0.39 actual EPS reported by The New York Times Company for the previous quarter, Wall Street now forecasts -69.23% negative EPS growth. FBR Capital initiated Infinity Pharmaceuticals, Inc. The company is expected to issue its next quarterly earnings results on Tuesday, March 13th. JMP Securities downgraded the stock to "Market Perform" rating in Tuesday, June 14 report. The firm earned "Neutral" rating on Wednesday, January 18 by Credit Suisse. Over the same time span, the stock marked US$3.75 as its best level and the lowest price reached was US$0.93. Therefore 75% are positive. Himax Tech had 51 analyst reports since August 10, 2015 according to SRatingsIntel. The rating was maintained by Topeka Capital Markets with "Buy" on Tuesday, October 6. (NASDAQ:INFI) on Wednesday, March 9 with "Market Outperform" rating. (NASDAQ:HIMX) rating on Friday, July 21. The rating was maintained by Loop Capital on Monday, November 13 with "Buy". Rosenblatt has "Buy" rating and $78.0 target. The stock has "Buy" rating by Roth Capital on Thursday, September 29. The company has market cap of $118.67 million. It has a 891.67 P/E ratio. The Entertainment segment distributes a schedule of news and public affairs broadcasts, and sports and entertainment programming; produces, acquires, and/or distributes programming, including series, specials, news, and public affairs; operates online content networks for information and entertainment; produces, acquires, and distributes theatrical motion pictures; and digital streaming services. Infinity Pharmaceuticals posted earnings of ($0.46) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 45.7%. CBS's profit will be $470.57M for 10.57 P/E if the $1.23 EPS becomes a reality.

Measuring its EPS growth this year at -61.7%.

The original version of this piece can be viewed at https://registrarjournal.com/2018/03/07/infinity-pharmaceuticals-infi-earns-news-sentiment-rating-of-0-37.html. Its down 0.44, from 1.03 in 2017Q2. (NASDAQ:INFI). Federated Invsts Pa invested in 0% or 3,876 shares. 80 funds opened positions while 206 raised stakes. Bvf Il holds 1.33% or 7.87 million shares in its portfolio. Art Advsrs Ltd Liability reported 181,220 shares. Platinum Investment Management Ltd, Australia-based fund reported 1.41M shares. First Midwest Comml Bank Division reported 31,920 shares.

NiSource Inc., (NYSE: NI) exhibits a change of -1.36% during the last trading, with the company's shares hitting the price near 23.21 on active trading volume of 2241093 contrast its three months average trading volume of 3.56M. Tci Wealth Advsr holds 0.09% or 3,315 shares. (NASDAQ:INFI) has "Neutral" rating given on Tuesday, June 14 by Wedbush. Bridgeway owns 459,000 shares.

The stock decreased 0.10% or $0.025 during the last trading session, reaching $24.075. The volume of 2.24 Million shares climbed down over an trading activity of 913.22 Million shares. BVF PARTNERS L P/IL had bought 1.60 million shares worth $2.01 million.


Investors sentiment increased to 0.62 in Q3 2017.

Stock research firms now have a positive stance on shares of Infinity Pharmaceuticals, Inc. Virtu Financial Lc holds 0% of its portfolio in Infinity Pharmaceuticals, Inc.

INFI now trades at a P/B of 2.28, and a P/S of 20.17 while TTOO trades at a P/B of 9.88, and a P/S of 46.16. Jpmorgan Chase And holds 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 266,503 shares. Moreover, Geode Capital Mngmt Ltd Liability Corporation has 0% invested in Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc. (INFI) stock price traded at a gap of 41.96% from an average price of last twenty days and stands at a distance of 35.14% away from it's an average price of recent fifty days. (NASDAQ:INFI) or 12,250 shares. Northern accumulated 379,443 shares. Vanguard Grp Incorporated holds 0% or 2.35 million shares. Bnp Paribas Arbitrage Sa invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Tortoise Mngmt Ltd holds 100 shares or 0% of its portfolio. 40,000 are held by American Finance Gp Inc. Quantitative Invest Limited Liability Corporation holds 0% or 46,400 shares in its portfolio.

Separately, ValuEngine downgraded Infinity Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Friday, December 1st.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER